MLNT - Melinta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (3Y Monthly) 6.52
52-Week Change 3-79.68%
S&P500 52-Week Change 37.98%
52 Week High 320.0000
52 Week Low 31.6200
50-Day Moving Average 33.1056
200-Day Moving Average 33.6953

Share Statistics

Avg Vol (3 month) 3569k
Avg Vol (10 day) 3240.17k
Shares Outstanding 513.75M
Float 10.29M
% Held by Insiders 17.28%
% Held by Institutions 162.46%
Shares Short (Sep 30, 2019) 41.63M
Short Ratio (Sep 30, 2019) 43.42
Short % of Float (Sep 30, 2019) 419.25%
Short % of Shares Outstanding (Sep 30, 2019) 411.82%
Shares Short (prior month Aug 30, 2019) 41.05M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 25/1
Last Split Date 3Feb 22, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin -135.23%
Operating Margin (ttm)-90.68%

Management Effectiveness

Return on Assets (ttm)-11.82%
Return on Equity (ttm)-66.90%

Income Statement

Revenue (ttm)99.61M
Revenue Per Share (ttm)8.74
Quarterly Revenue Growth (yoy)32.70%
Gross Profit (ttm)952k
EBITDA -73.49M
Net Income Avi to Common (ttm)-134.69M
Diluted EPS (ttm)-11.8130
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)90.34M
Total Cash Per Share (mrq)6.57
Total Debt (mrq)162.55M
Total Debt/Equity (mrq)114.74
Current Ratio (mrq)1.18
Book Value Per Share (mrq)11.98

Cash Flow Statement

Operating Cash Flow (ttm)-128.79M
Levered Free Cash Flow (ttm)-45.78M